Methods: A survey was conducted in primary and secondary

learn more care patients presenting to two outpatient gastroenterology clinics in Jakarta and Padang, Indonesia, using a culturally adapted and translated version of the Rome III FGID Questionnaire that had been locally validated. Patients who were found to have organic disease during investigation were excluded. Result: A total of 142 patients (47 males and 95 females) consecutively recruited, with 50 FD, 44 IBS, and 48 both FD-IBS. Female was predominant in FD (F = 37/50, 74%; age mean 47.38, SD 17.25), IBS (F = 28/44, 63.64%; age mean 38.64, SD 14.00) and both/FD-IBS (F = 30/48, 52.5%; age mean 42.17, SD 15.48). The most bothersome complaint was abdominal pain in FD (10) and FD – IBS (23) and abdominal discomfort in IBS patients (14). In IBS-only patients, 13 had IBS-C (constipation predominant), 8 had IBS-D (diarrhea predominant), 18 had IBS-M (mixed) and 5 had IBS-U (unspecified). In patients who had both FD and IBS, 20 had IBS-C, 11 had IBS-D and 17 had IBS-M pattern. Clinically, in FD-only patients, 44% patients were diagnose as FD. In IBS-only patients, none was diagnose as IBS. In FD-IBS, only 10% diagnose as IBS, 37.5% as FD and

none as both. Previous treatment consisted of PPI 54.9%, H2RA 28.9%, check details probiotics 23.2%, gastrokinetics 18.3%, traditional herbs 17.6%, anxiolytic 16.2%, laxatives 13.4%, fibre supplement 10.6% and anti-spasmodics 5.6%. On their previous treatment 63.4% felt some improvement, 11.3% felt no change, and 1.4% felt worse. Conclusions: Overlapping diagnosis of both FD and IBS was common with abdominal pain commonly present in both disorders. This overlapping symptom

may cause mis-diagnosis in clinical setting. Key Word(s): 1. Functional dyspepsia; 2. irritable bowel syndrome; 3. overlapping diagnoses Presenting Author: MARCELLUS ABDULLAH Additional Authors: MARCELLUS ABDULLAH, KAKA RENALDI, DADANG MAKMUN, AZIZ RANI Corresponding Author: MARCELLUS ABDULLAH Affiliations: University of Indonesia Inositol monophosphatase 1 Faculty of Medicine, University of Indonesia Faculty of Medicine, University of Indonesia Faculty of Medicine, University of Indonesia Faculty of Medicine Objective: Chronic gastritis is frequent in daily practice. One of the agents that can improve gastric inflammation, mucus and mucosal healing is fucoidan. Fucoidan derived from Cladosiphon okamuranus tokida is a sulphated polysacharide algae from Japan. The aim of this study to reveal the efficacy of fucoidan in treating dyspepctic symptoms, endoscopy and histopathologic scores of gaster. Methods: This is an open study on 31 dyspeptic patients who went to polyclinic gastroenterology Ciptomangunkusumo Hospital Jakarta. The patients were given oral fucoidan 100 mg perday for 28 days.